JP2006506378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506378A5 JP2006506378A5 JP2004546158A JP2004546158A JP2006506378A5 JP 2006506378 A5 JP2006506378 A5 JP 2006506378A5 JP 2004546158 A JP2004546158 A JP 2004546158A JP 2004546158 A JP2004546158 A JP 2004546158A JP 2006506378 A5 JP2006506378 A5 JP 2006506378A5
- Authority
- JP
- Japan
- Prior art keywords
- memantine
- donepezil
- medicament
- use according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 14
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 9
- 229960004640 memantine Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229960003530 donepezil Drugs 0.000 claims description 7
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000007370 cognitive improvement Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42091802P | 2002-10-24 | 2002-10-24 | |
| PCT/GB2003/004549 WO2004037234A2 (en) | 2002-10-24 | 2003-10-23 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011195242A Division JP2011246491A (ja) | 2002-10-24 | 2011-09-07 | １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506378A JP2006506378A (ja) | 2006-02-23 |
| JP2006506378A5 true JP2006506378A5 (enExample) | 2009-09-10 |
Family
ID=32176649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004546158A Pending JP2006506378A (ja) | 2002-10-24 | 2003-10-23 | １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 |
| JP2011195242A Pending JP2011246491A (ja) | 2002-10-24 | 2011-09-07 | １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011195242A Pending JP2011246491A (ja) | 2002-10-24 | 2011-09-07 | １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US20040087658A1 (enExample) |
| EP (2) | EP1556019A2 (enExample) |
| JP (2) | JP2006506378A (enExample) |
| KR (2) | KR100777904B1 (enExample) |
| CN (1) | CN100339070C (enExample) |
| AU (1) | AU2003274353B2 (enExample) |
| CA (1) | CA2502432A1 (enExample) |
| EA (1) | EA008863B1 (enExample) |
| GE (1) | GEP20094759B (enExample) |
| MX (1) | MXPA04006900A (enExample) |
| NO (1) | NO20052462L (enExample) |
| PL (1) | PL376476A1 (enExample) |
| TW (1) | TW200418446A (enExample) |
| UA (1) | UA83645C2 (enExample) |
| WO (1) | WO2004037234A2 (enExample) |
| ZA (1) | ZA200503204B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| CN100339070C (zh) * | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| AU2004316119B2 (en) * | 2003-10-22 | 2008-04-24 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies |
| SI1703902T1 (sl) * | 2004-01-05 | 2011-02-28 | Merz Pharma Gmbh & Co Kgaa | Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| AU2005309601A1 (en) * | 2004-11-23 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| US20060211650A1 (en) * | 2004-12-16 | 2006-09-21 | Forest Laboratories, Inc. | Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| CA2592605C (en) | 2004-12-27 | 2010-12-07 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| CA2604617C (en) * | 2005-04-28 | 2014-06-17 | Eisai R&D Management Co., Ltd. | Composition containing anti-dementia drug |
| US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| ATE481094T1 (de) | 2005-12-22 | 2010-10-15 | Kiacta Sarl | Behandlung von diabetischer nephropathie |
| EP2420235A1 (en) * | 2006-10-27 | 2012-02-22 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US20100168174A1 (en) * | 2007-07-13 | 2010-07-01 | Eisai R&D Management Co., Ltd. | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| TW201010691A (en) * | 2008-06-12 | 2010-03-16 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders |
| KR20110050739A (ko) * | 2008-09-10 | 2011-05-16 | 메르츠 파마 게엠베하 운트 코. 카가아 | 이명에서 인지 장애의 치료를 위한 １-아미노-알킬시클로헥산 유도체 |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| MX353752B (es) | 2009-01-20 | 2018-01-26 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco. |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| TWI491395B (zh) | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
| JP5885668B2 (ja) | 2009-12-02 | 2016-03-15 | アダマス ファーマシューティカルズ， インコーポレイテッド | アマンタジン組成物および使用方法 |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| TR201001117A1 (tr) | 2010-02-15 | 2011-09-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Dimebolin ve memantin kombinasyonları |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| EP2578212B1 (en) * | 2010-05-24 | 2016-07-06 | Farmalider, S.A. | Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses |
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA2938671A1 (en) * | 2014-02-04 | 2015-08-13 | Forest Laboratories Holdings Limited | Donepezil compositions and method of treating alzheimer's disease |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
| EP3310785B1 (en) | 2015-06-19 | 2024-11-20 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| KR101882224B1 (ko) | 2015-09-02 | 2018-07-26 | 한국프라임제약주식회사 | 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물 |
| US10835499B2 (en) | 2015-12-30 | 2020-11-17 | Corium, Inc. | Systems and methods for long term transdermal administration |
| WO2017127306A1 (en) | 2016-01-18 | 2017-07-27 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| WO2017215593A1 (en) | 2016-06-13 | 2017-12-21 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
| CA3027300C (en) | 2016-06-13 | 2023-08-08 | Syneurx International (Taiwan) Corp. | Co-crystals of lithium benzoate and uses thereof |
| CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
| EP3490544A1 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Memantine transdermal delivery systems |
| KR102424270B1 (ko) | 2016-07-27 | 2022-07-25 | 코리움, 인크. | 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템 |
| JP7071330B2 (ja) | 2016-07-27 | 2022-05-18 | コリウム， インコーポレイテッド | 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| US20200166526A1 (en) * | 2017-07-25 | 2020-05-28 | William Beaumont Hospital | Methods for diagnosing and treating alzheimer's disease |
| CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| IL288505B1 (en) | 2019-05-31 | 2026-07-01 | Tecnimede Sociedade Tecnico Medicinal Sa | Immediate release fixed dose memantine and donepezil |
| FR3110393B1 (fr) * | 2020-05-20 | 2022-05-06 | Grn Consulting | Compose et composition pour induire une neuroprotection |
| EP4572852A1 (en) | 2022-08-19 | 2025-06-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7305644A (enExample) | 1972-04-20 | 1973-10-23 | ||
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| NL195004C (nl) * | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| US4849222A (en) | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
| US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| EP0724432B1 (en) | 1993-10-22 | 2002-09-18 | Genentech, Inc. | Methods and compositions for microencapsulation of antigens for use as vaccines |
| US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| UA61962C2 (uk) | 1997-06-30 | 2003-12-15 | Мерц Фарма Гмбх Унд Ко. Кгаа | Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування |
| MX339071B (es) * | 1999-03-31 | 2016-05-09 | Janssen Pharmaceutica Nv | Almidon pregelatinizado en una formulacion de liberacion controlada. |
| TW593223B (en) * | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| EP1509232B1 (en) * | 2002-05-31 | 2008-11-19 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| CN100339070C (zh) * | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| WO2008139984A1 (en) * | 2007-04-26 | 2008-11-20 | Eisai R & D Management Co., Ltd. | Cinnamide compounds for dementia |
-
2003
- 2003-10-23 CN CNB200380104613XA patent/CN100339070C/zh not_active Expired - Fee Related
- 2003-10-23 EP EP03758338A patent/EP1556019A2/en not_active Withdrawn
- 2003-10-23 UA UAA200504854A patent/UA83645C2/ru unknown
- 2003-10-23 MX MXPA04006900A patent/MXPA04006900A/es active IP Right Grant
- 2003-10-23 US US10/691,895 patent/US20040087658A1/en not_active Abandoned
- 2003-10-23 PL PL03376476A patent/PL376476A1/xx not_active Application Discontinuation
- 2003-10-23 AU AU2003274353A patent/AU2003274353B2/en not_active Ceased
- 2003-10-23 GE GEAP20038812A patent/GEP20094759B/en unknown
- 2003-10-23 CA CA002502432A patent/CA2502432A1/en not_active Abandoned
- 2003-10-23 TW TW092129457A patent/TW200418446A/zh unknown
- 2003-10-23 EA EA200500699A patent/EA008863B1/ru unknown
- 2003-10-23 KR KR1020057007052A patent/KR100777904B1/ko not_active Expired - Fee Related
- 2003-10-23 WO PCT/GB2003/004549 patent/WO2004037234A2/en not_active Ceased
- 2003-10-23 EP EP10181505A patent/EP2260839A3/en not_active Withdrawn
- 2003-10-23 JP JP2004546158A patent/JP2006506378A/ja active Pending
- 2003-10-23 KR KR1020077016542A patent/KR100852834B1/ko not_active Expired - Fee Related
-
2005
- 2005-04-20 ZA ZA200503204A patent/ZA200503204B/en unknown
- 2005-05-23 NO NO20052462A patent/NO20052462L/no not_active Application Discontinuation
-
2008
- 2008-02-27 US US12/072,539 patent/US20090124659A1/en not_active Abandoned
-
2010
- 2010-03-22 US US12/661,639 patent/US20100227852A1/en not_active Abandoned
-
2011
- 2011-09-07 JP JP2011195242A patent/JP2011246491A/ja active Pending
-
2014
- 2014-05-16 US US14/280,405 patent/US20140371260A1/en not_active Abandoned
-
2016
- 2016-01-28 US US15/008,646 patent/US20160136144A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/178,606 patent/US20210169864A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| RU2007140348A (ru) | Способы и композиции для лечения заболеваний цнс | |
| JP2016138142A (ja) | 大うつ病を有する患者において減量療法を提供する方法 | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2017506624A5 (enExample) | ||
| JP2018502168A5 (enExample) | ||
| JP2022009121A (ja) | 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための５－ｈｔ６受容体アンタゴニスト | |
| US20100035927A1 (en) | Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP7123205B2 (ja) | 経口用医薬組成物 | |
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| IE851848L (en) | Propiophenone compound against sexual dysfunction | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| JP2021530568A5 (enExample) | ||
| AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| HUP0200655A2 (hu) | Osanetant alkalmazása kedélyállapot-rendellenességek kezelésére használható gyógyszerek előállítására | |
| CN115607545A (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| JP2022071083A (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| CN114080221B (zh) | 用于减轻疼痛的布洛芬与曲马多的组合 | |
| JPWO2009022740A1 (ja) | イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤 | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| JP4993998B2 (ja) | イブプロフェンを含有する医薬組成物 | |
| JP2005527634A (ja) | 緊張型頭痛の治療にミルナシプランを使用する方法 | |
| GB2543484A (en) | Ketamine for the treatment of somatoform pain disorder | |
| JP2010518052A (ja) | 性機能障害の予防および治療に有用な薬物の調製のための、ニューロキニンａのｎｋ２受容体に対する化合物である拮抗薬の使用 |